FWM
REGN icon

Focused Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Focused Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4,000
Closed -$211K – 890
2020
Q3 		$211K Buy
+4,000
New +$2.43M 0.05% 138
2020
Q2 		– Sell
-6,400
Closed -$30K – 810
2020
Q1 		$30K Buy
+6,400
New +$2.64M 0.01% 331

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Focused Wealth Management's REGN Position: Q2 2026 in Review

Focused Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 384 shares — an estimated $297K sold.

Focused Wealth Management first reported a position in REGN in Q4 2015 and held it in 29 quarters. The position peaked at $856K in Q3 2018. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Focused Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Focused Wealth Management sold 384 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $297K.
  • Focused Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 29 quarters.
  • Focused Wealth Management's Regeneron Pharmaceuticals position peaked at $856K in Q3 2018.
  • 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Focused Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.